Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by bringon10baggeron Aug 27, 2019 11:27am

160 Views

Post# 30070012

RE:RE:how long is this efficacy of 2b? 3 weeks?

Agree Pandora, I'll be very selective of my comments, may upset LFF....lol. Simply put.....The timing is is what it is, mgmt providing full transparency of when to expect results, just a bump in the road. Originally it was late summer, then Q3 and now Q4, a few months is miniscule with respect to the potential of the prize. These guys are doing their DD to mazimize shareholder value.............................

Pandora wrote: "how long is this efficacy of 2b? 3 weeks?"

"had been late calendar Q3 2019, but this will now occur in calendar Q4 2019."

Notice he did not repeat the phrase "late calendar" in reference to Q4 so maybe it will be early calendar or mid calendar? :-))

As I said -- don't expect it and maybe you will be pleasantly surprised.